Singapore’s Bio*One Capital Eyes Services, Data and Devices In Investment Push: An Interview With PharmAsia News
This article was originally published in PharmAsia News
The biomedical investment arm of Singapore’s state-run investment firm EDBI, gives PharmAsia News insight into where its next round of investments are aimed.
You may also be interested in...
SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions
GSK And Singapore's Economic Development Board Finance Asian Public Health Research Through Public-Private Fund
SINGAPORE - The National University of Singapore has set up an initiative to advance public health and healthcare delivery in Asia. The 10-year initiative will be funded with S$17 million ($12.3 million) from the GSK-EDB Trust Fund, a joint fund created by GlaxoSmithKline and Singapore's Economic Development Board
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.